Nestle invests $65M in Seres' D round

Microbiome company Seres Health Inc. (Cambridge, Mass.) closed a $65 million series D round from the Nestle Health Science subsidiary of Nestle SA (SIX:NESN). The investment comes one month after Seres' $48 million series C round from undisclosed public investors (see BioCentury Extra, Dec. 2, 2014).

Last month, Seres said it would begin a Phase III study of SER-109 in 2015 to prevent recurrence of Clostridium difficile infections . Seres discovered the orally available mixture of undisclosed bacteria using its Ecobiotic platform, which identifies the physiological condition of the microbiome in a healthy person, compares it to the condition in a sick person and determines what organisms could be added to convert the diseased microbiome back to a healthy state. ...